Prosecution Insights
Last updated: November 20, 2026

Francini Alvarenga Fonseca Lopez, USPTO Patent Examiner

Listed by the USPTO as FONSECA LOPEZ, FRANCINI ALVARENGA

Tech Center 1600 • Art Units: 1635 1645 1682 1685

This examiner grants 27% of resolved cases

Analysis

FONSECA LOPEZ, FRANCINI ALVARENGA is assigned to Tech Center 1600 and art unit 1635. The profile includes 33 resolved cases, an allowance rate of 27.3%, an interview lift of 32.6%, and a median of 1552 days to allowance. The case volume is limited, but the figures identify interview activity and a recorded prosecution timeline for examiner-specific planning.

The companies listed are DeepMind Technologies Limited, Fujifilm Holdings Corporation, and Canon Inc. The firms are Alford Law Group, Inc., Barclay Damon, LLP, and Bridgeway IP Law Group, PLLC. Counsel can use these entries to locate prior matters and assess possible procedural context. Decisions about claim scope, amendments, and interview use should remain tied to the particular application history.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

27.3%
Allow Rate
-32.7% vs TC avg
107
Total Applications
+32.6%
Interview Lift
1552
Avg Prosecution Days
Based on 33 resolved cases, 2023–2026

Rejection Statute Breakdown

30.7%
§101 Eligibility
9.0%
§102 Novelty
31.7%
§103 Obviousness
24.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18058110 PREDICTION OF PEPTIDE CLEAVAGE IN POLYPEPTIDES THROUGH PHYSICS-BASED SIMULATIONS Final Rejection Genentech, Inc.
18412092 QUALITY MANAGEMENT METHOD FOR SPECIFIC CELL AND METHOD OF PRODUCING SPECIFIC CELL Non-Final OA FUJIFILM Corporation
18498968 ANALYSIS APPARATUS Non-Final OA Canon Kabushiki Kaisha
18372565 METHODS FOR ALLELE CALLING AND PLOIDY CALLING Non-Final OA Natera, Inc.
18191723 RNA SCAFFOLDED WIREFRAME ORIGAMI AND METHODS THEREOF Final Rejection Massachusetts Institute of Technology
17414480 METHODS FOR IDENTIFYING NEOANTIGENS Non-Final OA Dana-Farber Cancer Institute, Inc.
19340736 PLATFORMS, SYSTEMS, AND METHODS FOR MULTI-OBJECTIVE OPTIMIZATION AND COMPARATIVE ANALYSIS FOR SYNTHETIC BIOLOGY DEVELOPMENT Non-Final OA X Development LLC
17872823 DIABETES PREDICTION USING GLUCOSE MEASUREMENTS AND MACHINE LEARNING Final Rejection DexCom, Inc.
17553295 System and Method for Control of Sequencing Process Non-Final OA LIFE TECHNOLOGIES CORPORATION
17780037 METHOD AND SYSTEM USING INTEGRATIVE MULTI-OMIC DATA ANALYSIS FOR EVALUATING THE FUNCTIONAL IMPACTS OF GENOMIC VARIANTS Non-Final OA KONINKLIJKE PHILIPS N.V.
18224308 METHOD AND APPARATUS FOR PROVIDING A PHARMACOKINETIC DRUG DOSING REGIMEN Non-Final OA TAKEDA PHARMACEUTICAL COMPANY LIMITED
18026058 METHODS AND COMPOSITIONS FOR PROGNOSING GLIOBLASTOMA OR BREAST CANCER Final Rejection The Johns Hopkins University
17806075 TRANSFORMER-BASED GRAPH NEURAL NETWORK TRAINED WITH STRUCTURAL INFORMATION ENCODING Non-Final OA Microsoft Technology Licensing, LLC
17435852 QUANTITATION OF SECONDARY DEGRADATION IN UNAFFECTED JOINTS RESULTING FROM OSTEOARTHRITIS OF THE KNEE OR HIP Non-Final OA Smith & Nephew Orthopaedics AG
17795465 DISEASE DETECTION AND TREATMENT BASED ON PHENYLACETYL GLUTAMINE LEVELS Final Rejection The Cleveland Clinic Foundation
17924948 SYSTEMS AND METHODS FOR DETECTING GENOME EDITS Final Rejection MONSANTO TECHNOLOGY LLC
18443879 EARLY DETECTION AND INTERVENTION OF AT-RISK SUBJECTS FOR PRODROMAL PARKINSON'S DISEASE Non-Final OA The Chinese University of Hong Kong
18179144 METHODS FOR CELL LABEL CLASSIFICATION Non-Final OA Becton, Dickinson And Company
18182846 RISK STRATIFICATION METHOD FOR THE DETECTION OF CANCERS IN PRECANCEROUS TISSUES Non-Final OA The Curators of the University of Missouri
18025603 METHODS AND SYSTEMS FOR SEQUENCE AND VARIANT CALLING Non-Final OA Ultima Genomics, Inc.
18347691 APPARATUS AND METHOD FOR SELECTING CATHODE MATERIAL FOR SODIUM-ION BATTERY USING MACHINE LEARNING Non-Final OA FOUNDATION OF SOONGSIL UNIVERSITY-INDUSTRY COOPERATION
18027571 PREDICTING SYMMETRICAL PROTEIN STRUCTURES USING SYMMETRICAL EXPANSION TRANSFORMATIONS Non-Final OA DeepMind Technologies Limited
17849269 DETERMINING A DISTRIBUTION OF ATOM COORDINATES OF A MACROMOLECULE FROM IMAGES USING AUTO-ENCODERS Final Rejection DeepMind Technologies Limited
18042285 IDENTIFYING A TARGET NUCLEIC ACID Non-Final OA IMPERIAL COLLEGE INNOVATIONS LIMITED
17876528 BASE CALLING USING MULTIPLE BASE CALLER MODELS Final Rejection ILLUMINA, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Francini Alvarenga Fonseca Lopez's allowance rate?

27.3% of resolved applications examined by Francini Alvarenga Fonseca Lopez were allowed (33 resolved cases), compared with 51.3% across Art Unit 1635 over the last five years.

Does an interview help with examiner Francini Alvarenga Fonseca Lopez?

This examiner's interview lift is +32.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Francini Alvarenga Fonseca Lopez take to allow a patent?

Applications allowed by Francini Alvarenga Fonseca Lopez took 1,552 days on average from filing to allowance.

Which art unit does examiner Francini Alvarenga Fonseca Lopez work in?

Francini Alvarenga Fonseca Lopez examines applications in Art Unit 1635 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month